Rezultati - D Y Kim
- Showing 1 - 18 results of 18
-
1
-
2
Mutant MotB proteins in Escherichia coli od David F. Blair, D Y Kim, Howard C. Berg
Izdano 1991Artigo -
3
-
4
-
5
-
6
-
7
-
8
-
9
Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions od Shanshan Lu, Sang Joon Kim, Ho Sung Kim, Choong Gon Choi, Young‐Min Lim, E. J. Kim, D. Y. Kim, S. H. Cho
Izdano 2013Artigo -
10
-
11
Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data od Yasir Qazi, David R. Shaffer, Bruce Kaplan, D.Y. Kim, Fu L. Luan, V.R. Peddi, Fuad S. Shihab, Stephen J. Tomlanovich, S. Yilmaz, Kevin McCague, Dharmesh Patel, S. Mulgaonkar
Izdano 2016Artigo -
12
-
13
Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model od J.-H. Choi, J.-H. Choi, D.-Y. Kim, Jung Hee Yoon, H.-Y. Youn, Jun Yi, H.-I. Rhee, Kyung Hwan Ryu, Kiwon Jung, C.-K. Han, W.-J. Kwak, Y.-B. Cho
Izdano 2002Artigo -
14
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea od Y. S. Kim, S. J. Kim, Jai Hoon Yoon, Ki Tae Suk, J. B. Kim, Dong Joon Kim, D. Y. Kim, Hyun-Jun Min, S. H. Park, Woon Geon Shin, K. H. Kim, H. Y. Kim, Gwang Ho Baik
Izdano 2011Artigo -
15
The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery od Young Ho Yun, Y.A. Kim, Ye Min, S. Park, Young‐Joo Won, D. Y. Kim, Il Ju Choi, Young‐Woo Kim, S. J. Park, J.H. Kim, D. H. Lee, Seok‐Jun Yoon, Seung‐Yong Jeong, Dong‐Young Noh, D.S. Heo
Izdano 2012Artigo -
16
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study od S.-E. Lee, Soo Young Choi, Ho Young Song, S H Kim, M.-Y. Choi, J. S. Park, H.-J. Kim, S.-H. Kim, Dae Young Zang, Subi Oh, H. Kim, Y. R., Jae‐Yong Kwak, Jeong‐Ah Kim, D.-Y. Kim, Yeung‐Chul Mun, W. S. Lee, Myung Hee Chang, Jinny Park, J. H. Kwon, D.-W. Kim
Izdano 2016Artigo -
17
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view od D.H. Lim, D Y Kim, Minyong Kang, Y I Kim, Won Ki Kang, C K Park, S Kim, Jung Hyun Noh, Jae‐Won Joh, Seong Ho Choi, Tae Sung Sohn, Jin Seok Heo, C. H. Park, J O Park, Jeong Eun Lee, Y J Park, Hae-Seon Nam, Wonse Park, Yong Chan Ahn, Seung Jae Huh
Izdano 2004Artigo -
18
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors od S.-H. Kim, Hari Menon, Saengsuree Jootar, T Saikia, J. Kwak, S.K. Sohn, J. S. Park, Seong Hyun Jeong, Hyung‐Jun Kim, Y.-K. Kim, Subi Oh, Heonoh Kim, Dae Young Zang, Joo-Seop Chung, Hyeon Ju Shin, Yashwant Lamture, Jeong‐Ah Kim, D.-Y. Kim, Chul Won Choi, Sung Sup Park, H. L. Park, G. Y. Lee, Dongwook Cho, Jae‐Soo Shin, D.-W. Kim
Izdano 2014Artigo
Iskalna orodja:
Sorodne teme
Medicine
Internal medicine
Biology
Gastroenterology
Surgery
Gene
Oncology
Biochemistry
Cancer
Chemotherapy
Immunology
Physics
Adjuvant
Cell biology
Cohort
Confidence interval
Environmental health
Gene expression
Genetics
Imatinib
Imatinib mesylate
Incidence (geometry)
Lymphoma
Multivariate analysis
Myeloid leukemia
Optics
Pathology
Pharmacology
Population
Radiation therapy